Merck Stock Down 4% Since Q2 Results: How to Play the Stock

Merck (MRK) shares declined 4% following Q2 results, where EPS beat estimates but revenue fell 2% to $15.8 billion, primarily due to a significant 48% drop in Gardasil sales offsetting strong 9% growth in Keytruda. Despite concerns over Keytruda's 2028 patent expiration and increasing competitive pressure, Merck is strategically mitigating future revenue gaps through a robust pipeline, including successful new product launches like Capvaxive and Winrevair, the $10 billion Verona Pharma acquisition, and a new $3 billion cost optimization initiative, positioning the company for long-term resilience.

Analysis

Merck's recent stock decline of 4% post-earnings reflects a mixed second-quarter performance where near-term challenges are overshadowing strategic long-term initiatives. While adjusted EPS of $2.13 beat estimates, it represented a 7% year-over-year decline, and total revenues fell 2% to $15.8 billion. This top-line weakness was driven by a significant 48% drop in sales for Gardasil in the first half of 2025, primarily due to a temporary halt in shipments to China to manage excess inventory, a situation now expected to last through the end of 2025. This downturn masked the continued strength of Keytruda, which grew 9% to $7.96 billion and now constitutes over half of the company's pharmaceutical sales. However, the heavy reliance on Keytruda is a central risk, amplified by its patent expiration in 2028 and emerging competition from drugs like Summit Therapeutics' ivonescimab. In response, management is executing a multi-pronged strategy to mitigate this concentration risk. This includes aggressive pipeline expansion, with the phase III pipeline nearly tripling since 2021, and successful new launches like Capvaxive and Winrevair. Furthermore, the $10 billion acquisition of Verona Pharma for its COPD drug Ohtuvayre and a new cost-saving initiative targeting $3 billion by 2027 demonstrate proactive measures to reshape the future revenue base. Despite a narrowed 2025 sales forecast, the stock trades at an attractive forward P/E of 8.64, well below industry and historical averages, suggesting the market may be pricing in the headwinds more heavily than the long-term growth potential.

Key Decisions for Investors

• Investors should weigh the current attractive valuation against significant near-term risks, including the prolonged disruption of Gardasil sales in China and Japan, which is expected to persist through 2025.
• Monitor key catalysts that could de-risk the future revenue profile, such as the upcoming September FDA decision on the subcutaneous formulation of Keytruda and the initial sales performance of new products like Capvaxive, Winrevair, and the newly acquired Ohtuvayre.
• Assess management's execution on its pipeline and M&A strategy, as the success of its nearly tripled phase III pipeline and the integration of the Verona Pharma deal are critical to offsetting the Keytruda patent cliff in 2028.
• Consider the stock's underperformance and low forward P/E of 8.64 as a potential entry point for a long-term position, contingent on the company demonstrating a clear path to growth beyond Keytruda in the coming quarters.